FDA Approves Empliciti for Multiple Myeloma

Share this content:
FDA Approves Empliciti for Multiple Myeloma
FDA Approves Empliciti for Multiple Myeloma

MONDAY, Nov. 30, 2015 (HealthDay News) -- Empliciti (elotuzumab), in combination with two other drugs, has been approved by the U.S. Food and Drug Administration to treat multiple myeloma. The drug is only approved for patients who have already been given one to three prior therapies for the disease.

Empliciti, a monoclonal antibody, activates the body's immune system to attack and kill multiple myeloma cells, the FDA explained Monday in a news release. It is approved in combination with another FDA-approved treatment for multiple myeloma, Revlimid (lenalidomide), and the corticosteroid dexamethasone.

Empliciti was evaluated in clinical studies involving 646 people whose multiple myeloma returned or didn't respond to prior treatment. Patients who took the three-drug combination including Empliciti had an average disease-progression delay of 19.4 months, compared to 14.9 months among those who took the other two drugs without Empliciti.

Empliciti's most common side effects included fatigue, diarrhea, fever, constipation, cough, peripheral neuropathy, nasal infection, respiratory infection, loss of appetite, and pneumonia.

The drug is marketed by New York City-based Bristol-Myers Squibb.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Ancient Gene Protects Elephants From Cancer

Ancient Gene Protects Elephants From Cancer

The LIF6 gene destroys cells with damaged DNA

Reasons for Undergoing Cosmetic Procedures Explored

Reasons for Undergoing Cosmetic Procedures Explored

Psychological and emotional motivations more likely in patients wanting acne scar tx, tattoo removal

DNR Orders Linked to Increased Mortality in Older Adults

DNR Orders Linked to Increased Mortality in Older ...

Early versus late DNR tied to shorter median length of stay in hospitalized adults aged 65 years and older

is free, fast, and customized just for you!




Already a member?

Sign In Now »